{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"data_sharing_plan":["IPD Sharing (as of February 2023): No"],"condition":["Triple Negative Breast Neoplasms","Metastatic Breast Cancer","Advanced Solid Tumors","Triple Negative Breast Cancer","Metastatic Colon Cancer","Rectal Cancer","Hormone Receptor Positive Breast Carcinoma","Breast Neoplasms","HER2-negative Breast Cancer"],"disease":["Her2-negative Breast Cancer","Triple Negative Breast Neoplasms","Metastatic Breast Cancer","Advanced Solid Tumors","Triple Negative Breast Cancer","Metastatic Colon Cancer","Rectal Cancer","Hormone Receptor Positive Breast Carcinoma","Breast Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2251920"],"location":["United States"],"study_start_month":["11"],"keyword":["Colorectal","VEGF","Breast"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer","description":"An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.","dates":{"creation":"2017-11-15"},"accession":"2251920","cross_references":{"ClinicalTrials___gov":["NCT03251378"]}}